NIH Locks Down Blood and Tissue from Sneaky Foreign Spies
Published Date: 12/12/2025
Notice
Summary
The NIH now requires stronger security for human biospecimens funded by them to protect people and national safety. This affects researchers and labs handling these samples, with new rules effective since October 24, 2025. These changes help stop risky access by foreign countries and don’t add extra costs but do require careful handling.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 3 costs, 0 mixed.
Applies to all NIH‑funded biospecimens
The policy applies to all human clinical and research biospecimens obtained from U.S. persons that are collected, obtained, stored, used, or distributed with any on-going or new NIH funding mechanism, regardless of NIH funding level. This rule became effective October 24, 2025 and covers biospecimens from U.S. persons whether or not they are identifiable.
Ban on sharing with countries of concern
Entities that hold NIH‑funded human biospecimens of U.S. persons are prohibited from directly or indirectly distributing those biospecimens to institutions or parties located in 'countries of concern' as determined under 28 CFR 202.601. The prohibition applies to biospecimen distribution unless one of the policy's limited exceptions is met.
Limited exceptions allow some transfers
Biospecimens may be shared with countries of concern only in limited circumstances: (1) transactions required or authorized by Federal law or international agreements (including global health) or necessary for compliance with Federal law; (2) rare and compelling cases where needed capability/expertise exists only in that country and the individual consented; or (3) at the request of the individual for their diagnosis, prevention, or treatment and in compliance with applicable Federal laws. Any such sharing must meet these specified conditions.
Documentation and retention requirement
NIH requires entities that share or distribute biospecimens to countries of concern under an allowable exception to retain documentation of those transactions, including the quantity and content of material shared, and to provide that documentation to NIH upon request. Entities must keep these records for any sharing done under the policy's limited circumstances.
Exemption for already public/commercial cell lines
The policy does not apply to cell derivative products or cell lines derived from human biospecimens of U.S. persons that were commercially or publicly available prior to the policy's effective date of October 24, 2025. However, cell lines that had agreements to be made commercially or publicly available but were not yet available on or after the effective date remain covered.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2025-22617, Foreign-Trade Zone (FTZ) 189, Notification of Proposed Production Activity; Plascore, Incorporated; (Metal, Aramid Paper and Plastic Honeycomb); Zeeland, Michigan
Plascore, Inc. in Zeeland, Michigan wants to start making special honeycomb and metal products using some imported materials under Foreign-Trade Zone rules. This change could help them save money and speed up production by handling certain parts more easily. The government is reviewing their plan, which was officially submitted on December 8, 2025.
Next: 2025-22619, Biosimilar User Fee Act; Stakeholder Consultation Meetings on Biosimilar User Fee Act Reauthorization; Request for Notification of Stakeholder Intention To Participate
The FDA is inviting patients, consumer groups, and other stakeholders to join monthly meetings starting April 2026 to help shape the next Biosimilar User Fee Act, which expires in September 2027. These talks will guide how fees for biosimilar drug makers are collected in the future, ensuring everyone’s voice is heard. If you want in, let the FDA know by January 30, 2026!